Genetic variation at the CYP2C locus and its association with torsemide biotransformation
- 12 September 2006
- journal article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 7 (3) , 200-211
- https://doi.org/10.1038/sj.tpj.6500410
Abstract
In 97 unselected volunteers and two additional homozygous carriers of CYP2C9*3, we investigated the oral clearance of torsemide in relation to 37 polymorphisms at the CYP2C gene locus. Torsemide total oral clearance was linearly associated with the number of CYP2C9*3 alleles (geometric mean: 59, 40 and 20 ml/min in carriers of no, one and two alleles) and so were the methyl- and ring-hydroxylation but not the carboxylation clearance. Haplotypes including the CYP2C9*3 allele were similarly associated with the clearances but no other variant and no haplotype not including the CYP2C9*3 variant. The extended haplotype length (EHL) of the CYP2C9 haplotypes was positively associated with higher activity of the gene product. Torsemide total oral clearance was predictable with r2=82.1% using plasma concentrations at 0.5, 1, 2 and 24 h. In conclusion, torsemide's biotransformation strongly depended on the CYP2C9*3 variant but no other. Higher clearance CYP2C9 haplotypes appear to be evolutionarily selected.Keywords
This publication has 48 references indexed in Scilit:
- Searching for signals of evolutionary selection in 168 genes related to immune functionHuman Genetics, 2005
- P450 2C18 Catalyzes the Metabolic Bioactivation of PhenytoinChemical Research in Toxicology, 2005
- The Case for Selection at CCR5-Δ32PLoS Biology, 2005
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005
- Haploview: analysis and visualization of LD and haplotype mapsBioinformatics, 2004
- Differential Contribution of Active Site Residues in Substrate Recognition Sites 1 and 5 to Cytochrome P450 2C8 Substrate Selectivity and RegioselectivityBiochemistry, 2004
- The International HapMap ProjectNature, 2003
- Detecting recent positive selection in the human genome from haplotype structureNature, 2002
- Intra‐individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9activityBritish Journal of Clinical Pharmacology, 2002
- Some suggestions for measuring predictive performanceJournal of Pharmacokinetics and Biopharmaceutics, 1981